Oligonucleotide microarrays were used to analyse gene expression profiles in human ZR75-1 breast cancer cells in the presence of 17 -oestradiol and oestrogen antagonists. Differential gene expression of a number of genes was confirmed by quantitative RNA analysis. In addition to known oestrogenresponsive genes, an appreciable number of novel targets were identified, including growth factors and components of the cell cycle, adhesion molecules, enzymes, signalling molecules and transcription factors. The most pronounced oestrogen-sensitive gene was that for the cytochrome P450-IIB enzyme, involved in metabolising steroids and xenobiotics, which was increased 100-fold over a 24 h period. It is a direct target gene for oestrogens, because its expression was increased in the presence of cyclohexamide. In contrast, expression of cytochrome P450-IIB was not detected in human MCF7 breast cancer cells. Expressions of the cationic amino acid transporter E16, gap junction protein and insulin-like growth factor binding protein 4 were also markedly increased by oestrogens, but the kinetics of induction varied according to the target gene. With the exception of the cationic amino acid transporter E16 and the insulin-like growth factor binding protein 4, the expression of the majority of the genes was unaffected by antioestrogen treatment. Further analysis of this set of markers will provide alternative approaches to the investigation of the mitogenicity of oestrogens in breast cancer cells.
INTRODUCTION
The oestrogen receptor (ER) is an important pharmaceutical target for hormone replacement treatment in menopausal women and for endocrine adjuvant therapy for the management and, recently, the prevention of breast cancer (Jordon & Morrow 2000) . A wide repertoire of structurally distinct compounds bind to ER with differing degrees of affinity and potency. Some of these compounds, such as the natural ligand, 17 -oestradiol, act solely as receptor agonists, whereas others, such as faslodex (ICI 182, 780) , function as pure antagonists (Wakeling & Bowler 1988 , Howell et al. 2000 . A third category, termed selective ER modulators (SERMs), are capable of acting as either agonists or antagonists, depending on the target cell type or tissue (Dhingra 1999 , Jordon & Morrow 2000 . For example, tamoxifen and raloxifen function as antagonists in the breast and as agonists in bone, but differ in their effects in the endometrium, where tamoxifen is an agonist and raloxifen is an antagonist (Levenson & Jordan 1999) . Responses also vary according to the promoter and the ER isoform targeted. Thus, although both 17 -oestradiol and antioestrogens are capable of stimulating transcription from activator protein-1-containing genes, this seems to be achieved primarily by means of ER in the presence of 17 -oestradiol, but by either ER or ER in the presence of antioestrogen (Paech et al. 1997) .
To date, a relatively small number of oestrogen target genes have been identified in tissues or in cell lines. These include pS2, identified by differential screening of a cDNA library from MCF7 breast cancer cells (Masiakowski et al. 1982) , and cathepsin D (Westley & May 1987) . More recently, antioestrogens were shown to stimulate the expression of quinone reductase by using the technique of RNA differential display (Montano & Katzenellenbogen 1997) . New approaches based on DNA microarrays have been used to characterise distinctive gene expression patterns in human mammary epithelial cells and breast cancers (Perou et al. 1999) . A similar approach has been used to monitor gene expression during breast cancer progression (Sgroi et al. 1999) and to characterise breast tumours (Nacht et al. 1999 , Bertucci et al. 2000 . In this way, it is possible to identify clusters of genes that show similar patterns of expression when cells are grown under different conditions.
We have used a gene expression profiling approach to identify ER target genes in human ZR75-1 breast cancer cells. Complementary RNA generated from cells grown in the presence of 17 -oestradiol, 4-hydroxytamoxifen, raloxifen or faslodex were analysed for hybridisation to Affymetrix HuGeneFL oligonucleotide microarrays and differential expression was confirmed by subsequent analysis of RNA from ZR75-1 and MCF-7 cells. In this way, we have identified known and novel oestrogen target genes.
MATERIALS AND METHODS

Cell culture
Human ZR75-1 and MCF-7 breast cancer cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (Gibco Brl, Paisley, UK) and 10 8 M 17 -oestradiol. For MCF7 cell culture, insulin (10 µg/ml) and glutamine (4 mM) were added to the medium. The cells were plated in 175 cm 2 flasks (Tissue Culture Flask 750 ml 3045, Falcon, London, UK). To prepare total RNA, each cell line was cultured for 5 days in phenol-free medium containing 10% charcoal-dextran-stripped fetal bovine serum (CSS) and then maintained in phenol-free medium containing 10% CSS and 10 µg/ml cycloheximide, with no hormone, 10 8 M 17 -oestradiol, 10 7 M 4-hydroxytamoxifen, 10 7 M raloxifen or 10 7 M faslodex for defined periods as specified below.
Expression profiling
Total RNA was extracted from cells using Trizol reagent (Life Technologies, Paisley, UK). Polyadenylate (poly(A)+) RNA was purified from total RNA with oligo-dT-linked Oligodetex resin (Qiagen, Crawley, UK). Two micrograms poly(A)+ RNA were converted into double-stranded cDNA (ds-cDNA) by using Superscript Choice System (Life Technologies) with an oligo-dT primer containing a T7 RNA polymerase promoter. After second-strand synthesis, the reaction mixture was extracted with phenol-chloroform-isoamyl alcohol, and ds-cDNA was recovered by ethanol precipitation. Subsequently, complementary RNA (cRNA) was generated by in vitro transcription using a T7 Megascript Kit (Ambion AMS, Abingdon, UK) with 25% of the ds-cDNA template in the presence of a mixture of unlabelled ATP, CTP, GTP and UTP and biotin-labelled CTP and UTP (bio-11-CTP and bio-16 UTP (Enz, Farmingdale, CN, USA)). Biotin-labelled cRNA was purified using an RNeasy affinity column (Qiagen), and fragmented randomly to sizes ranging from 35 to 200 bases by incubating at 94 C for 35 min in 1 Affymetrix fragmentation buffer (Affymetrix, Stanford, CA, USA). The hybridisation solution contained 100 mM 2-[N-morpholino]ethanesulfonic acid (MES), 1 M Na + , 20 mM EDTA and 0·01% Tween 20 and was 0·1 µg/µl (final concentration) of fragmented cRNA. After hybridisation at 45 C overnight, Affymetrix HuGeneFL arrays were washed in a fluidics station with stringent buffer (100 mM MES, 0·1 M Na+, 0·01% Tween 20) and non-stringent buffer (6 SSPE, 0·01% Tween 20) and stained with streptavidin-phycoerythrin after antibody amplification. DNA chips were read at a resolution of 6 µm with an Affymetrix GeneArray scanner.
Data analysis
The arrays were analysed using GeneChip 3.1 software, comparing arrays with similar signal-to-noise ratios and similar backgrounds. These arrays showed similar percentages of genes expressed. The average fluorescence intensity for each Affymetrix HuGeneFL chip was scaled to the same value so that every chip could be compared directly. For each time point, the data were analysed using the six possible comparisons (four different treatments compared two-by-two). The results were sorted using Access application and each gene selected was analysed individually in a global way (logic results for the following six comparisons: 4-hydroxytamoxifen-, raloxifen-and faslodex-treated with 17 -oestradioltreated, 4-hydroxytamoxifen-treated with raloxifenand faslodex-treated, and raloxifen-treated with faslodex-treated).
RNA analysis
Specific probes for each gene were designed, based on a BLAST search with mRNA, PCR fragment and primer sequences. Primers were selected using Primer3 (Rozen & Skaletsky 2000) .
A 367 bp fragment from the human transducer of ErbB2,1 (Tob) cDNA and a 291 bp fragment from the human receptor interacting protein (RIP) 140 cDNA were amplified by PCR using pfu DNA polymerase (Stratagene, Amsterdam, The Netherlands) and the following primers: Tob-F: taccactgccacttttgctg; Tob-R: actgaggttaagggggctgt; RIP-F: cctggcagatgattcagaca; RIP-R: gcccaactcctgt gttcact. They were then cloned into pCR-Blunt II-Topo vector (Invitrogen, Paisley, UK). RNase protection probes were generated by in vitro transcription of the plasmids described above (linearized with BamHI) and of the pTRIactin-125-human plasmid (Ambion), using T7 RNA polymerase. RNase protection assays were carried out using the RPA III Kit (Ambion). Total RNA was hybridised with specific probes at 42 C overnight, followed by digestion with RNase A/T1. Finally, protected fragments were ethanol precipitated and separated on a 5% polyacrylamide sequencing gel.
Northern blots and hybridisations were performed by standard techniques using 10 µg total RNA and radioactive probes generated by random priming of sequence-verified PCR products amplified with elongase (Gibco Brl) and obtained with the following primers: E16-F: ctgttctgggaggtggacat; E16-R: cgtttgtcagtggagtgtgg; inositol 1,3,4 triphosphate 5/6 kinase (IP3K)-F: cagactcaccccatcacctt; IP3K-R: ttgttgggtcctcagtttcc; gap junction protein (Gap)-F: ctcctcctgggtacaagctg; Gap-R: cctccaccggat caaaatta; insulin-like growth factor binding protein 4 (IGFBP4)-F: gcccaagaggactgagactg; IGFBP4-R: tggtgcaacaaccagaccta; cytochrome P450-IIB (Cyt)-F: tcctttctgaggttccgaga; Cyt-R: tggaatggaagaggaaggtg; glucose-6-phosphate dehydrogenase (G6PD)-F: atttgccaacaggatcttcg; G6PD-R: tcccacctctcattctccac; immediate early response 3 (IEX)-F: gacctcagcactttc ctcca; IEX-R: tacagcagggggaacatctc; tropomyosin 4 (TPM4)-F: cttaagacggaggccatttg; TPM4-R: gatgttt gtcctgcatggtg. The amount of TPM4 was used as an internal standard.
RESULTS
We compared gene expression profiles in human breast cancer ZR75-1 cells grown in the presence of four different ligands for the ER by exploiting GeneChip methodology. The ligands tested were the natural hormone 17 -oestradiol, the SERMs 4-hydroxytamoxifen and raloxifen, and the pure antagonist faslodex. As a first step to the identification of clusters of genes of which the expression is regulated by each ligand, we analysed patterns of expression by using Affymetrix HuGeneFL oligonucleotide arrays representing 5600 human genes. Cells were initially maintained in medium deprived of oestrogens for 5 days and then treated with ligand for 6 or 24 h in the presence of cyclohexamide to ensure that changes in gene expression were primary responses. RNA was isolated from the cells and analysed for pS2 gene expression, a wellcharacterised target gene for 17 -oestradiol (Brown et al. 1984 , Chalbos et al. 1993 . This marker of oestrogen action was significantly increased by 17 -oestradiol relative to the oestrogen antagonists (data not shown). Poly(A)-containing RNA was isolated and used to prepare cDNA samples that were then transcribed to generate biotin-labelled cRNA to hybridise with the GeneChip HuGeneFL probe array. Expression profiles were determined using cRNA generated from cells treated with ligands for 6 or 24 h. Hybridisation signals were first analysed using GeneChip 3.1 software and genes of interest were selected using Access software. The results were then analysed for each gene in six different comparisons at two different time-points (see Materials and Methods). This last selection allowed us to discard a large number of false-positive results.
A total of 53 genes was identified, the relative expression of which differed by more than 1·5-fold (Table 1 ; parts 1 and 2). The samples derived from cells treated with 17 -oestradiol were used as a baseline in the differential gene expression comparisons, as this highlighted the effects of the different antioestrogens. The majority of these genes were more highly expressed in the presence of the hormone, so that the fold change in the presence of antioestrogens was negative. The expression of several known oestrogen-target genes (pS2, cyclin D1, cathepsin D) and many novel genes was greater in cells grown in the presence of 17 -oestradiol. The most pronounced change observed was that for Cyt ( Fig. 1a) , expression of which in the presence of 17 -oestradiol was 20-fold that in the presence of 4-hydroxytamoxifen, 45-fold that with raloxifen and 70-fold that with faslodex. Inspection of the 20 probe pairs (Fig. 1a) corresponding to perfectmatch and mismatch oligonucleotides indicated that the majority exhibited similar changes. Under these circumstances, differences in gene expression of as little as 1·5-fold were subsequently confirmed by quantitative RNA analysis (see below).
Expression of potential ER target genes, predicted from the profiling analysis, was then analysed by northern blotting and RNase protection experiments. As an internal control we monitored TPM4 mRNA levels which, as confirmed by the DNA chip analysis, were unaffected by any of the ligands. Expression levels were compared with those in a  1.  1. Identification of candidate ER target genes by hybridisation to oligonucleotide arrays. Summary of results from hybridisation to oligonucleotide arrays representing 5600 expressed sequences. Labelled RNA probes derived from ZR75-1 cells grown in the presence of cyclohexamide and 17 -oestradiol (E), 4-hydroxytamoxifen (T), raloxifen (R) or faslodex (F) for 6 h were hybridised to arrays. For each sample, the average difference (AD) in hybridisation intensity between the perfect-match and the mismatch oligonucleotides represent the transcript level. The fold changes (FC) indicated were calculated by GeneChip 3.1 software using the 17 -oestradiol sample as a baseline. The negative and positive FCs correspond to decreases and increases respectively. One gene, MSX-2, is represented by two different probe sets on the Chip array control sample from cells grown in the presence of cyclohexamide but in the absence of any ER ligand, to investigate the hormonal regulation of expression of each gene. Consistent with the DNA chip analysis we found that Cyt gene expression was markedly stimulated by 17 -oestradiol relative to that in antioestrogens (Fig. 1b) , increasing with time to approximately 100-fold after 24 h. Surprisingly, we were not able to detect expression of Cyt in the human MCF-7 breast cancer cell line (data not shown).
We then analysed expression of a number of additional genes in ZR75-1 cells predicted to be differentially expressed in the presence of different ER ligands according to the HuGeneFL chip analysis, as shown in Figures2 and 3a. Thus 17 -oestradiol increased the expression of the cationic amino acid transporter E16 by approximately fivefold after 6 h and 10-fold over a 24 h period, whereas tamoxifen and raloxifen, but not faslodex, increased expression up to twofold during this period. Levels of mRNA for Gap were markedly increased by 17 -oestradiol (10-to 15-fold), but were completely unaffected by antagonist. 17 -Oestradiol also increased the expression of G6PD and IP3K, both increasing by up to fivefold but with different kinetics. We next examined the regulation of a number of genes in both ZR75-1 and MCF7 cells (Fig. 3b) . IGFBP4 gene was stimulated rapidly and markedly by 10 to 15-fold in both cell lines and the IEX-1 gene was also regulated similarly in both cell lines, although the absolute levels of expression differed significantly. Finally, we examined the expression of the nuclear receptor cofactor RIP140 and Tob by RNase mapping and found that they were also increased by up to threefold in the presence of 17 -oestradiol (Fig. 4) . Although these genes are all oestrogen target genes, their expression was regulated with different kinetics. Increases in
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Gap junction  2. Northern blot analysis of E16, Gap (alpha 1) and G6PD mRNA expression in ZR75-1 treated by different ER ligands in the presence of cyclohexamide. The cells were cultured for 6 or 24 h in the presence of 17 -oestradiol (E), 4-hydroxytamoxifen (T), raloxifen (R) or faslodex (F), or in the absence of any ligand (NL). The Gap transcript is 3038 bases long; another transcript corresponding to connexin 43 was detected with the same probe, but its expression level was constant (data not shown). mRNAs for G6PD, IP3K, Gap, IEX-1 and Tob were apparent within 6 h and there was no further increase after 24 h. In contrast, although E16 and IGFBP4 mRNAs were increased within 6 h, they were substantially greater after 24 h, whereas the increases in IEX-1 and Tob mRNA were transient. The majority of these genes were unaffected by antioestrogen treatment, with the exception of E16 and IGFBP4, which increased about twofold in the presence of 4-hydroxytamoxifen and raloxifen.
DISCUSSION
The characterisation of gene expression profiles for tumour cell lines provides a framework for assessing the biological significance of expression patterns in a specific tumour (Perou et al. 1999 . We focused on target genes for 17 -oestradiol in view of its importance as a mitogen in a subset of ER-positive cell lines and tumours. In this study we identified a number of oestrogen-regulated genes, all of which were direct targets, as they were differentially expressed in the presence of cyclohexamide. We have organised the genes into clusters according to their function. Several genes are implicated in cell proliferation. Thus Tob, which was first identified by its ability to interact with ErbB-2, may have antiproliferative activity (Matsuda et al. 1996 , Yoshida et al. 1997 . IGFBP4 has been proposed to modulate binding of IGFs to their receptors and thereby regulate IGF action. Interestingly, IGFBP4 induction by 17 -oestradiol has recently been described by other groups (Glantschnig et al. 1998 , Zazzi et al. 1998 . Given that IGFBP4 has been found to inhibit the T   4h  24h  8h  2h   Tob   βactin   6  3  6  3  6  3  6  3  6  3  6  3  6  3  6  3  6 growth of breast cancer cells driven by IGF pathways (Corcoran et al. 1996) , it is conceivable that IGFBP4 expression alters the sensitivity of breast cancers to the mitogenic effects of oestrogens. IEX-1, which is an immediate early response gene induced by serum growth factor, is a member of the nuclear factor-B/Rel (NF-B) family of transcription factors and may be important in cell survival (Wu et al. 1998) . Finally, the identification of cyclin D1 was expected, as it clearly has an important role in cell cycle progression in response to mitogens, including oestrogens (Planas-Silva & Weinberg 1997 , Prall et al. 1997 . A number of differentially expressed genes encode membrane-associated proteins or proteins involved in adhesion, migration or communication between cells. For example, Gap alpha 1, a member of the connexin gene family, is a component of gap junctions that are important in cellular differentiation and organogenesis, and loss of its function is correlated with progression to a malignant phenotype (Locke 1998) . The observation that its expression is upregulated by oestrogens in ZR75-1 cells is consistent with the relatively well differentiated phenotype of this ER-positive breast cancer cell line.
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A third group consists of genes that encode enzymes involved in cell metabolism. The G6PD gene encodes a cytosolic enzyme the main function of which is to produce NADPH, a key electron donor in the defence against oxidising agents and in reductive biosynthetic reactions. Interestingly, a positive effect of 17 -oestradiol on G6PD activity in MCF7 cells has previously been described (Monet et al. 1987 , Thomas et al. 1990 ). The Cyt family of enzymes are involved in steroid metabolism and in the metabolism of various xenobiotics (Nelson et al. 1993 , Honkakoski & Negishi 2000 . These enymes are highly expressed in the liver, where they have been shown to be induced by a number of xenobiotics acting through nuclear receptors such as constitutively acting receptor, pregnane X receptor and peroxisome proliferator activating receptor alpha. t is difficult to judge whether the expression of this enzyme in breast cancer cells may affect their senstivity to xenobiotics, and the importance of environmental oestrogens as a risk factor for breast cancer remains rather speculative.
The relevance of the majority of oestrogen target genes to oestrogen-dependent growth is unclear, but further analysis may provide new markers for the analysis of hormone responses in specific tumours. Thus it would be informative to examine them in a large number of ER-positive tumour samples to determine if their expression correlates with their response to endocrine therapy.
